Oral Minoxidil Clears Hair-Loss Trial Hurdle, Eyes Regulatory Approval
Veradermics’ oral minoxidil candidate VDPHL01 posted positive Phase II/III results for mild-to-moderate pattern hair loss, with 79% (single-dose 8.5 mg daily) and 86% (twice-daily) showing significant hair growth versus 36% on placebo, and a safety profile similar to placebo. If approved, it would be the first new oral treatment for pattern baldness in about 30 years, offering a non-hormonal option with an extended-release design to minimize cardiovascular risks.